Intelligent Pharma signs two research contracts with American company SciClone Pharmaceuticals
The operation, which will allow Sciclone to use technology developed by Intelligent Pharma to better understand how specific molecules work, will help drivethe Catalan biotechnology company’s international expansion.
Biotechnology company Intelligent Pharma, based at the Barcelona Science Park (PCB), has signed their first two research contracts in the United States. These agreements are with SciClone Pharmaceuticals, a multinational located in Silicon Valley that specializes in developing drugs for the Chinese market related to oncology and infections. SciClone Pharmaceuticals is traded on the Nasdaq stock exchange.
This operation will allow SciClone to use technology developed by Intelligent Pharma to better understand how specific molecules work. Ignasi Belda, CEO of the Catalan company, explained that “this is an important milestone in our company’s growth. We aim to complete our international process this year and increase our market share in the United Kingdom, Switzerland, the United States and Germany.”
Intelligent Pharma started up an affiliate at the Heidelberg Technology Park one year ago (see the related news published on the Biocat website), an area where the majority of Germany’s biopharmaceutical industry is located. They have also started up several collaborative projects in the United Kingdom.
The company currently has a team of 20 employees and focuses their activity on two lines of business: offering scientific/computational services for companies that work to discover new drugs or new applications of known drugs, and providing technical services for companies that want to computerize their processes in chemical, biological and pharmaceutical research. They were recently chosen as the most innovative company with the best potential for growth in Catalonia (Emprenedor XXI Award) and as the most innovative company to come out of the University of Barcelona (Senén Vilaró Award).
For the fourth consecutive year, Intelligent Pharma will participate in BIO Washington (from 27 to 30 June). They will join the Catalan delegation of companies and organizations coordinated by Biocat. Ignasi Belda is one of the Catalan bio-entrepreneurs that remain committed to this convention –the most important in the sector worldwide– and is convinced of the positive results obtained, both fromthe partnering sessions offered at BIO and through their presence in the BioRegion of Catalonia pavilion.